MedTrace Logo

The Influence of Secretin Stimulated Pancreatic Secretion on ctDNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal Adenocarcinoma

NCT06807112 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 39

Last updated 2025-02-04

No results posted yet for this study

Summary

The goal of this study is to assess the influence of pancreatic secretion stimulation by intravenously administered secretin on circulating tumor DNA in patients with pancreatic ductal adenocarcinoma. Additional aim of the study is to analyse a role of specific biomarkers in determining the prognosis of this disease. The main question o answer is:

Does intravenous secretin administration potentiate the release of circulating tumor DNA in patients with pancreatis ductal adenocarcinoma?

Additional question is:

Is there a biomarker specific and sensitive enough to help to predict the prognosis and the at the time status of the disease?

Participants scheduled for surgical treament due to pancreatic ductal adenocarcinoma will be included and stimulated with intravenously administered secretin, their peripheral blood samples will then be analyzed for ctDNA levels.

Conditions

Interventions

OTHER

Intravenously administered secretin

16 micrograms of liquid secretin will be one-time intravenously administered to patients with PDAC during the first hour of surgery. Four peripheral blood samples will then be collected. Plasmatic levels of ctDNA will be measured. Plasmatic levels of biomarkers such as mRNA, miRNA, siRNA, exoRNA, S100 proteins and amino acids, isolated from the same blood samples, will be measured and analyzed in correlation to tumor volumometry, survival rate etc. in specific intervals during follow-ups.

Sponsors & Collaborators

  • Military University Hospital in Prague, Czech Republic

    collaborator UNKNOWN

  • Charles University, Czech Republic

    lead OTHER

Principal Investigators

  • Jan Bureš, prof., MD, CSc., FCMA · Military University Hospital in Prague

  • Kristýna Pončáková, MD · Military University Hospital in Prague

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-09
Primary Completion
2026-06-30
Completion
2027-02-01

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06807112 on ClinicalTrials.gov